

1 **SOCIODEMOGRAPHIC CHARACTERISTICS OF SARS-CoV-2 SEROSURVEILLANCE**
2 **STUDIES WITH DIVERSE RECRUITMENT STRATEGIES, CANADA, 2020 TO 2023**

3 Matthew J. Knight¹, Yuan Yu¹, Jiacheng Chen¹, Sheila F. O’Brien^{2,3}, David L. Buckeridge^{1,4},
4 Carmen Charlton^{5,6}, W. Alton Russell^{1,4}

5 1. Department of Epidemiology, Biostatistics and Occupational Health, School of Population and
6 Global Health, McGill University, Montreal, Canada

7 2. Canadian Blood Services, Ottawa, Canada

8 3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada

9 4. COVID-19 Immunity Task Force, Montreal, Canada

10 5. Canadian Blood Services, Edmonton, Canada

11 6. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

12 **Corresponding author:** Matthew J. Knight (matthew.knight@mail.mcgill.ca), +1-613-854-9571
13 Suite 1200, McGill College Avenue, Montreal, QC, Canada H3A 1G1

14 **Keywords:** Representativeness; Surveillance; COVID-19

15

16

17

18

19

20 **ABSTRACT**

21 **Background.** Serological testing was a key component of severe acute respiratory syndrome
22 coronavirus-2 (SARS-CoV-2) surveillance. Social distancing interventions, resource limitations,
23 and the need for timely data led to serosurveillance studies using a range of recruitment
24 strategies, which likely influenced study representativeness. Characterizing representativeness in
25 surveillance is crucial to identify gaps in sampling coverage and to assess health inequities.

26 **Methods.** We retrospectively analyzed three pre-existing longitudinal cohorts, two convenience
27 samples using residual blood, and one de novo probabilistic survey conducted in Canada
28 between April 2020 – November 2023. We calculated study specimen counts by age, sex,
29 urbanicity, race/ethnicity, and neighborhood deprivation quintiles. We derived a ‘representation
30 ratio’ as a simple metric to assess generalizability to a target population and various
31 sociodemographic strata.

32 **Results.** The six studies included 1,321,675 specimens. When stratifying by age group and sex,
33 65% of racialized minority subgroups were moderately underrepresented (representation ratio <
34 0.75). Representation was generally higher for older Canadians, urban neighborhoods, and
35 neighborhoods with low material deprivation. Rural representation was highest in a study that
36 used outpatient laboratory blood specimens. Racialized minority representation was highest in a
37 de novo probabilistic survey cohort.

38 **Conclusion.** While no study had adequate representation of all subgroups, less traditional
39 recruitment strategies were more representative of some population dimensions. Understanding
40 demographic representativeness and barriers to recruitment are important considerations when
41 designing population health surveillance studies.

42

43 INTRODUCTION

44 Serological surveillance is a critical input to infectious disease control, including pandemic
45 preparedness and response. In 2020, Canada launched the largest serological surveillance
46 program in its history to monitor population immunity to severe acute respiratory syndrome
47 coronavirus-2 (SARS-CoV-2), informing COVID-19 epidemiology and antibody dynamics.
48 Between April 2020 and February 2021, many studies began testing blood specimens for SARS-
49 CoV-2 antibodies [1–6]. Challenged by social distancing measures, studies used diverse
50 strategies to recruit participants or obtain blood samples. Recruitment strategy influences study
51 population’s characteristics and the extent to which participants represent the general population
52 [7].

53
54 Serosurveillance studies can be broadly categorized as convenience samples, de novo
55 probabilistic surveys, or pre-existing longitudinal cohorts. For SARS-CoV-2 serosurveillance,
56 many countries used convenience samples of residual blood specimens due to low operational
57 costs and ease of continued sample collection over time [1,2,8,9]. Convenience samples may
58 introduce selection bias if certain subpopulations are excluded or poorly represented [1,8].
59 Probabilistic serosurveys, also deployed in many regions to monitor SARS-CoV-2, can mitigate
60 selection biases by using stratified, weight-based approaches to recruitment. De novo designs
61 allow tailoring recruitment to study objectives [4,5,10–12]. However, probabilistic designs are
62 time- and resource-intensive and are sometimes limited by low response rates [6,13]. Sampling
63 within pre-existing longitudinal cohorts can improve efficiency by leveraging an established
64 sampling frame and study infrastructure. But this precludes tailoring the sampling frame to the
65 current research question, and generalizability may be limited by inclusion criteria or attrition.

66

67 In this study, we introduce a simple metric for diagnosing the representativeness of subgroups
68 within a study population. Using this metric, we evaluated the sociodemographic
69 representativeness of six SARS-CoV-2 serosurveillance studies with diverse recruitment
70 strategies by age, sex, race/ethnicity, urbanicity, and neighborhood measures of socioeconomic
71 deprivation. Our findings can inform serosurveillance study design for diverse pathogens.

72

73 **METHODS**

74 **Data**

75 We assessed representativeness by analyzing demographic data from six Canadian study
76 populations (Table 1). Here, we define a study to be representative if the sociodemographic
77 composition of the study population matched the census-based target population; we make no
78 assumptions of the sampling mechanism or inferential validity. This similarity suggests the
79 interpretation of an effect measure may be generalizable to the target population, but does not
80 assume the effect estimate, within an uncertainty interval, will be identical between the study and
81 target populations [14]. The six studies included one de novo cross-sectional probabilistic sample
82 (the Canadian COVID-19 Antibody and Health Survey 1 [CCAHS-1]), one open longitudinal
83 cohort recruited from a marketing research panel (Action to Beat Coronavirus study [Ab-C]),
84 two pre-existing closed longitudinal cohorts (the Canadian Longitudinal Study on Aging
85 COVID-19 Antibody Study [CLSA], the Canadian Partnership for Tomorrow's Health COVID-
86 19 Antibody Study [CanPath]), and two serial cross-sectional convenience samples that used
87 residual blood from blood donations (Canadian Blood Services [CBS]) and specimens collected
88 for outpatient laboratory testing (Alberta Precision Laboratories [APL]). The included studies

89 tested specimens collected from April 2020 to November 2023 with sample sizes ranging from
90 11,050 (CCAHS-1) to 1,039,298 (CBS). Inclusion criteria and enrollment procedures have been
91 described previously [1,2,6,12,15,16]. This study was reported using the STrengthening the
92 Reporting of OBservational studies in Epidemiology checklist for cross-sectional studies [17].

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114 **Table 1:** Summary of SARS-CoV-2 serological study designs included in the study.

Study	Design	Age	Region	Specimen type	Study time and size	De novo recruitment
Action to Beat Coronavirus (Ab-C)	Pre-existing longitudinal open research cohort	≥ 18	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK, YT ^a	Dried blood spot	25,110 specimens from 10,621 participants May 2020 - April 2022	No
Alberta Precision Laboratories (APL)	Serial cross-sectional convenience sample	≥ 0	AB	Heparinized plasma Plasma Serum	210,905 specimens from 187,887 participants April 2020 - October 2022	No
Canadian Blood Services (CBS)	Serial cross-sectional random sample	≥ 18	AB, BC, MB, NB, NL, NS, ON, PE, SK	Serum	1,035,580 specimens from 446,187 participants May 2020 - November 2023	No
Canadian Covid-19 Antibody and Health Survey 1 (CCAHS-1)	Prospective cross-sectional cohort with direct (ages 1-24) or multi-stage (ages ≥ 25) sampling	≥ 1	AB, BC, MB, NB, NL, NT, NS, NU, ON, PE, QC, SK, YT	Dried blood spot	11,050 specimens from 11,050 participants November 2020 - April 2021	Yes
Canadian Longitudinal Study on Aging (CLSA) ^b	Pre-existing longitudinal closed research cohort	≥ 51	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK	Dried blood spot Plasma	17,310 specimens from 17,310 participants October 2020 - August 2021	No
Canadian Partnership for Tomorrow's Health (CanPath) ^c	Pre-existing longitudinal closed research cohort	≥ 25	AB, BC, MB, NB, NL, NS, ON, PE, QC	Dried blood spot	21,720 specimens from 21,717 participants February 2021 - November 2021	No

115 *Notes:* ^aFour specimens were collected from Yukon territory and were excluded from all analyses. ^bComposed of
116 comprehensive sub-cohort and tracking sub-cohort that recruited participants from seven and 10 provinces,
117 respectively. ^cComposed of six distinct regional cohorts. AB: Alberta; BC: British Columbia; MB: Manitoba; NB:
118 New Brunswick; NL: Newfoundland and Labrador; NT: Northwest Territories; NS: Nova Scotia; NU: Nunavut;
119 ON: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YT: Yukon.

120

121

122

123 From each dataset, we extracted participants' age, sex, postal code, date of specimen collection,
124 and self-reported race/ethnicity. We used the postal code to classify participants' residence as
125 urban or rural and to assign participants' neighborhood to a quintile of the Pampalon material
126 and social deprivation indices [18]. Material deprivation is a composite measure of education,
127 employment, and income reflecting access to essential material resources. Social deprivation is a
128 composite measure of living alone, single-parent families, and people who are either separated,
129 divorced, and/or widowed, reflecting the fragility of social networks. Both measures are derived
130 from the 2016 Canadian census [19]. We used the date of specimen collection as the sample date
131 when available (CBS, APL); otherwise, we used the date of questionnaire completion (CanPath,
132 CCAHS-1, CLSA) or specimen receipt (Ab-C).

133
134 Race/ethnicity information was unavailable for the APL study. Deprivation indices were
135 available for the CBS, APL, CCAHS-1, and CLSA studies. Specimen counts for the CCAHS-1
136 study were rounded to base 2000 in accordance with data usage guidelines. Age was calculated
137 as the age at specimen collection (Ab-C, APL, CBS) or questionnaire completion (CanPath,
138 CLSA, CCAHS-1) and categorized as 0-17 years, 18-26 years, 27-36 years, 37-46 years, 47-56
139 years, or 57 years and older. For Ab-C specimens collected between December 2020 – April
140 2021 and July 2021 – September 2021, we used the 2019 baseline age since the age at current
141 collection could not be calculated. We categorized sex as male or female and excluded
142 participants who provided alternative responses (n = 138 [Ab-C]) from analyses involving
143 participant sex. Because race/ethnicity data collection varied between studies and differed from
144 census categorization, we re-classified participants as 'white' and 'racialized minority' and did
145 not analyze specific racialized minority groups (Supplementary Tables S1-S2). For studies

146 allowing multiple encounters with participants, we imputed missing variables when available for
147 another encounter (CBS, Ab-C, CLSA). We classified participants who identified as both white
148 and a racialized minority as a racialized minority, and we considered Indigenous identities as a
149 racialized minority but conducted sensitivity analyses with different classifications. Because only
150 CCAHS-1 collected specimens from the capital cities of the Canadian territories, we restricted
151 our primary analysis to specimens collected from Canadian provinces but assessed territorial
152 representativeness for CCAHS-1 separately. We excluded participants who did not meet the
153 inclusion criteria of their respective study and who were missing age, province/territory of
154 residence, or serology test result data. For the CBS study, we did not assess the
155 representativeness of the 0-17-year-old age group because there were no donors younger than 17.
156 We calculated specimen counts using complete cases within each set of demographic strata (e.g.,
157 participants missing race/ethnicity were excluded when stratifying by age, sex, and race/ethnicity
158 but not when stratifying by age, sex, and urbanicity).

159

160 **Representation ratio analysis**

161 To assess the representativeness of subgroups defined by one or more sociodemographic
162 variable, we derived a *representation ratio* by dividing the proportion of study specimens in a
163 sociodemographic subgroup by the proportion of participants in the subgroup from a target
164 population. A representation ratio less than one indicates the group is underrepresented relative
165 to the target population, and a ratio greater than one indicates overrepresentation. We defined the
166 target subgroup distribution using weighted 2016 Canadian census counts [19], restricting by age
167 and province/territory to match studies' inclusion criteria (Table 1) and rounded to the nearest
168 multiple of zero or five. We calculated representation ratios on unweighted study populations to

169 assess the unadjusted sociodemographic composition of each study except for CCAHS-1, due to
170 guidelines restricting unweighted analyses [6]. For the target distributions, race/ethnicity counts
171 were derived using the census population group variable and Indigenous-identifying respondents
172 were classified as racialized minorities [19]. Indigenous-identifying census respondents were
173 classified as racialized minorities, but were excluded when generating ratios for CLSA and
174 CanPath since Indigenous status was unavailable for most participants. We assessed the impact
175 of excluding Indigenous-identifying census respondents in a second sensitivity analysis. We
176 performed bootstrapping (n = 5000) to generate an uncertainty distribution for each
177 representation ratio.

178

179 **Sample count by strata analysis**

180 In some cases, statistical adjustment or subsampling may allow derivation of representative
181 population statistics from large, unbalanced study populations if there are sufficient samples
182 from less represented strata [20]. To inform whether this would be feasible in our study
183 populations, we assessed the number of strata with counts greater than 25 when grouped by age,
184 sex, province of residence, urbanicity, race/ethnicity, and date of specimen collection binned into
185 two-month intervals. All analyses were conducted in R version 4.3.1 [21].

186

187 **RESULTS**

188 **Study population**

189 During data pre-processing, we excluded 3,718 observations for CBS (0.4%), 3,871 for APL
190 (1.8%), 2,052 for Ab-C (7.6%), 2,024 for CLSA (10.5%), and 4,258 for CanPath (16.4%) due to
191 missing data or failure to meet inclusion criteria. We analyzed the remaining 1,035,580 (CBS),

192 210,905 (APL), 25,110 (Ab-C), 21,720 (CanPath), 17,310 (CLSA), and 11,050 (CCAHS-1)
193 observations (Supplementary Table S3). For Ab-C, CLSA, and CanPath, the minimum age of
194 participants included in our analysis (Table 1) was older than the minimum age specified in their
195 inclusion criteria [12,15,16]. Across studies, the largest number of observations were in the 57
196 and older age group (34.4% [CCAHS-1] – 91.4% [CLSA]). Observations for the 18-26-year-old
197 age group were generally low (0.0% [CanPath] – 5.6% [APL]) but were higher for CBS (10.6%)
198 and CCAHS-1 (11.8%). Among studies for which neighborhood deprivation was available,
199 specimen counts across social deprivation quintile were balanced, but only 8.2% (CBS), 8.4%
200 (APL), 9.6% (CLSA), and 13.1% (CCAHS-1) of specimens were provided from the most
201 materially deprived quintile of neighborhoods. Most studies skewed white (78.2% [Ab-C] –
202 94.7% [CLSA]) and female (52.3% [CLSA] – 65.6% [CanPath]), except CBS which skewed
203 white (81.7%) and male (58.2%). Rural specimens accounted for 8.6% (CanPath) – 17.6%
204 (CCAHS-1) of all specimens across studies. Convenience samples collected substantially more
205 specimens for each demographic strata compared to other recruitment strategies (Supplementary
206 Figures S1-S4).

207

208 **Representation ratio analysis**

209 Studies had reasonable representation across sexes (representation ratio 0.7-1.3; Figure 1) and,
210 when available, by social deprivation (Supplementary Figure S5). In all studies, racialized
211 minority subgroups were underrepresented (representation ratio < 1) for some age and sex strata
212 (Figure 2). Racialized minority representation, while still low, was often better in older age
213 groups (Ab-C, CanPath, and CLSA), but was better for younger age groups among women for
214 CBS. Urban regions produced larger representation ratios by age and sex strata than rural regions

215 in all studies (Figures 1-2). While APL had reasonable representation of all material deprivation
216 quintiles and rural residents (representation ratio 0.8-1.3), the CBS population skewed towards
217 less materially deprived neighborhoods and urban regions (though rural representation for CBS
218 was higher than the three longitudinal cohort studies). 18-26-year-old males were
219 underrepresented across most sex and urbanicity strata in all studies for which they were eligible
220 to be sampled.

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239



240

241 **Figure 1: SARS-CoV-2 serological study representativeness by sex, urbanicity, and**

242 **racial/ethnic identity.** Representativeness was calculated by dividing the proportion of study

243 specimens collected from a subgroup by the proportion of general population in the subgroup.

244 Total population counts were estimated using the 2016 Canadian census [19]. Bolded

245 representation ratios indicate greater than 95% of subgroup bootstrap replicates produced

246 representation ratios below 0.75. Bootstrapping was not performed for studies with weighted


247 representation ratios (CCAHS-1).

248

249

250

251



252

253 **Figure 2: SARS-CoV-2 serological study representativeness by age group, sex, urbanicity,**

254 **racial/ethnic identity, and material deprivation quintile.** Representativeness was calculated

255 by dividing the proportion of study specimens collected from a subgroup by the proportion of

256 general population in the subgroup. Total population counts were estimated using the 2016

257 Canadian census [19]. Material deprivation scores were not available for Ab-C and CanPath

258 studies. Bolded representation ratios indicate greater than 95% of subgroup bootstrap replicates

259 produced representation ratios below 0.75. Bootstrapping was not performed for studies with

260 weighted counts (CCAHS-1).

261
262 Among 18-46-year-olds, specimens from the Ab-C open cohort produced larger representation
263 ratios across sex and urbanicity strata compared to CanPath (Figure 2). Representation ratios of
264 18-46-year-old rural residents were generally larger across age and sex strata in CCAHS-1 than
265 several studies with probabilistic recruitment strategies (Ab-C, CanPath). Racialized minorities
266 aged 47 years and older were sufficiently represented (representation ratio 0.8-1.3) in the Ab-C
267 open cohort but were underrepresented in the CanPath and CLSA closed cohorts, except for
268 males aged 57 and older in CanPath. Of the two convenience samples, the CBS study was more
269 representative of participants aged 18-46 across sex and urbanicity strata, whereas the APL study
270 was more representative of individuals aged 47 and older. In CCAHS-1, the only study that
271 sampled in the three Canadian territories, 0-17-year-olds were underrepresented across sexes in
272 territorial specimens (Supplementary Figure S6). Bootstrapping revealed low uncertainty in
273 whether a representation ratio was greater or less than one for most subgroups (Supplementary
274 Figures S7-S13). A sensitivity analysis reclassifying mixed race/ethnicity participants as white
275 had little impact except for the Ab-C cohort, for which 55% of racialized minorities were
276 reclassified as white, leading to lower representation ratios (Supplementary Figures S14-S15).
277 Including Indigenous-identifying individuals as racialized minorities in the representation ratio
278 denominator for studies for which data were unavailable (CLSA and CanPath) had little impact
279 on findings (Supplementary Figure S16).

280

281 **Sample count analysis**

282 The convenience samples with large overall sample size produced substantially more cells with
283 counts greater than 25 across 4 levels of stratification compared to all other study designs in the
284 primary analysis (Table 2) and sensitivity analysis (Supplementary Table S4). Pre-existing

285 closed probabilistic cohorts (CLSA, CanPath) produced a greater proportion of cells with counts
286 greater than 25 than other probabilistic recruitment strategies (Ab-C, CCAHS-1) for all strata.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307 **Table 2:** Percentage of SARS-CoV-2 serology study demographic subgroups with greater than
 308 25 collected specimens.

Study (specimen count)	Months sampled	Demographic subgroups			
		Age, Sex, Province, Month	Age, Sex, Province, Urban, Month	Age, Sex, Province, Race/Ethnicity, Month	Age, Sex, Province, Race/Ethnicity, Urban, Month
CBS blood donor (1,035,580)	41	92%	74%	70%	52%
APL outpatient laboratory (210,905)	27	94%	84%	NA	NA
Ab-C open cohort (25,110)	18	31%	20%	20%	12%
CanPath closed cohort (21,720)	10	40%	31%	32%	26%
CLSA closed cohort (17,310)	11	50%	36%	34%	27%
CCAHS-1 closed cohort (11,050)	6	33%	20%	21%	13%

309 *Notes:* Date of sample collection was binned into 2-month intervals for each level of stratification. All
 310 specimen counts were unweighted.

311

312

313

314

315

316

317 **DISCUSSION**

318 In this study, we developed a simple method for characterizing study population
319 representativeness and applied it to describe the variability in sociodemographic
320 representativeness across six SARS-CoV-2 serosurveillance studies with diverse recruitment
321 strategies. No study was adequately representative of all sociodemographic subgroups.

322
323 Representation ratios are a flexible diagnostic measure for characterizing study populations.
324 Ratios can consider any combination of characteristics for which reliable estimates of their
325 distribution in a target population are available. Ratios can be used to compare study populations,
326 even when target populations differ, and can be estimated before and after application of sample
327 weights. Notably, representation ratios do not provide insights into the relationship between
328 participant characteristics and a study's estimand, and do not address unmeasured confounding
329 within subgroups.

330
331 Probabilistic surveys have traditionally been considered the 'gold standard' for obtaining
332 representative samples [7]. Use of administrative datasets to construct sampling frames often
333 provides superior population coverage compared to non-probability samples that rely on
334 participant self-selection. The statistical framework also permits estimation of sampling errors
335 and characteristics associated with non-response [22]. While resource constraints may limit the
336 ability of probabilistic designs to perform repeated specimen collection, non-probability
337 sampling within continuous streams of residual blood specimens, such as blood donors, may be
338 more feasible for modelling longitudinal trends, which can also incorporate complex geographic
339 structures [23]. The generalizability of probabilistic designs may also be limited if differences

340 between respondents and non-respondents are non-random [7]. Bias may be introduced via a
341 ‘healthy volunteer’ effect whereby cohort participants are healthier than the general population
342 [24], similar to the ‘healthy donor’ bias documented in blood donor research cohorts [25]. Where
343 available, response rates of the included studies were fairly low (23% [CCAHS-1], 25% [Ab-C]
344 [6,12]; these response rates exclude individuals who completed a questionnaire but did not
345 provide a blood sample). This suggests non-response bias could partially explain some of the
346 observed differences in representativeness between study designs. The above response rates are
347 consistent with other probabilistic serosurveys [11], although response rates as high as 69% have
348 been reported [10].

349
350 Many large-scale SARS-CoV-2 studies relied on blood donor and healthcare patient populations
351 for serology specimens [22,26]. Blood donors have been discounted as a population for public
352 health surveillance, while the potential for expanded screening of residual outpatient laboratory
353 samples remains unclear. However, we found the representativeness of these convenience
354 populations compared favorably to other designs for some sociodemographic dimensions. For
355 low- and middle-income countries with limited operational resources, leveraging residual blood
356 samples may provide a cost-effective avenue to obtain representative data. Future studies should
357 evaluate the potential of linkage to administrative datasets to better characterize
358 representativeness and derive statistical weights for adjustment. Gaps in demographic
359 representation may be overcome by synthesizing data from multiple surveillance streams, though
360 differences in choice of assay, use of venous blood draws or dried blood samples, and the format
361 or availability of variables can curtail the ability to synthesize data across studies [27,28].

362

363 Racialized minorities were underrepresented across all studies. Language barriers and skepticism
364 of research or medical institutions may contribute to poor representation of some minority
365 groups [29,30]. While use of stratified random sampling or sampling weights may improve
366 sample representativeness, they do not address the underlying individual and societal factors
367 governing participation in health research. Direct engagement and collaboration with community
368 members throughout the research cycle may mitigate recruitment barriers by facilitating trust,
369 reducing misinformation, and ensuring study materials are accessible [30,31]. Racialized
370 minorities may be better represented in healthcare cohorts like APL [32], though a lack of race-
371 based data in Canadian administrative healthcare datasets may make this difficult to measure
372 [33]. Notably, representation of racialized minorities improved as age increased in most studies
373 requiring participant opt-in (Ab-C, CLSA, CanPath), but young minorities exhibited better
374 representativeness compared to older subgroups in CBS. Lack of a standardized definition of
375 participant race/ethnicity impeded comparison across studies and prevented assessment of
376 representativeness by specific minority group.

377
378 Several other dimensions of representativeness varied across studies. The Ab-C open cohort was
379 substantially more representative of 18-46-year-olds across sex and urbanicity strata compared to
380 the CanPath longitudinal closed cohort (Figure 2). CLSA and CanPath recruited participants
381 aged 45-85 in 2010 and 35-74 in 2009, respectively, leading to older age distributions for their
382 COVID-19 sub-studies [15,16]. Between convenience samples, individuals residing in highly
383 materially deprived areas were underrepresented when using blood donations (representation
384 ratio 0.4–0.6), but not when using outpatient labs (representation ratio 0.9-1.2). Donor eligibility
385 criteria, along with the ‘healthy donor effect’ or other unmeasured socioeconomic factors, may

386 homogenize the demographic composition of the sampled donor pool [25]. Rural regions were
387 consistently underrepresented compared to urban counterparts in all studies, which may be due to
388 urban-centric recruitment patterns or willingness to travel for specimen collection (Figures 1-2).
389
390 The study had several limitations. First, our analysis considered representativeness by age, sex,
391 race/ethnicity, urbanicity, and neighborhood deprivation. Many other sociodemographic
392 dimensions are important considerations for representativeness in serosurveillance studies,
393 particularly those related to health and disability. We hypothesize a ‘healthy participant’
394 sampling bias may have led to underrepresentation of individuals with poor health and/or
395 disability in all study populations except outpatient laboratories [24,25]. Prior analyses of the
396 pre-existing longitudinal cohorts included in our study indicated participants are more educated
397 and/or have higher income than the general population [12,15,16], as are blood donors in the
398 United States [34]. Second, the measurement of race/ethnicity differed between studies.
399 Race/ethnicity options for CBS included four mutually exclusive categories, while the Ab-C,
400 CCAHS-1, CanPath, CLSA, and census datasets permitted selection of multiple racial/ethnic
401 identities. This necessitated dichotomizing the race/ethnicity variable as white or racialized
402 minority and may have biased the CBS representation estimate if individuals who identified as
403 mixed race/ethnicity selected their race/ethnicity as white during donation. Additionally, due to
404 unavailable Indigenous identity data, we modified our representation assessment for the CLSA
405 and CanPath studies by omitting Indigenous-identifying individuals from the census dataset. Our
406 sensitivity analysis suggests this did not substantially impact our findings (Supplementary Figure
407 S16). Third, we restricted our analysis to SARS-CoV-2 serostudies conducted within a single
408 country and used an acceptability level of underrepresentation that is context-specific and open

409 to interpretation. We focused on strata with fewer than 25 samples in our cell count analysis, but
410 this threshold was largely arbitrary. Fourth, we did not analyze factors shaping the
411 sociodemographic composition of each study, including intentional oversampling. For example,
412 CCAHS-1 used a stratified random sampling strategy that oversampled geographic regions with
413 greater COVID-19 prevalence and less populated regions to improve estimate precision. Less
414 populated areas of Canada often have fewer racialized minorities, which likely contributes to
415 lower representation ratios [6]. Understanding the causes and consequences of each study's
416 sociodemographic composition requires more detailed analysis than is presented here. Finally,
417 our study is not a comprehensive assessment of all SARS-CoV-2 serology studies conducted in
418 Canada. Demographic groups excluded here were evaluated elsewhere [35].

419
420 Understanding variability in demographic representation between study designs is an important
421 consideration when planning serosurveillance studies, which increasingly leverage pre-existing
422 samples or cohorts. This study provides a simple metric to evaluate and compare the
423 representativeness of study populations. We found that underrepresentation of racialized
424 minorities and younger age groups was common and not restricted to convenience samples,
425 which had better representation for some sociodemographic strata. This suggests that
426 representative estimates could be obtained in resource-constrained settings by leveraging lower-
427 cost approaches, such as existing blood or laboratory services, compared to large-scale
428 probabilistically sampled serosurveys. Identifying coverage barriers is vital to support adequate
429 representation and detection of disease trends within demographic subgroups. We also observed
430 differences in the measurement of participant race/ethnicity between studies. This highlights the
431 necessity for consistent, and sufficient, measurement of sociodemographic variables, along with

432 the need to adopt a standardized approach to the measurement of self-identified race/ethnicity in
433 Canada.

434

435 **ABBREVIATIONS**

436	Ab-C	Action to Beat Coronavirus
437	APL	Alberta Precision Laboratories
438	CanPath	Canadian Partnership for Tomorrow's Health
439	CBS	Canadian Blood Services
440	CCAHS-1	Canadian COVID-19 Antibody and Health Survey 1
441	CLSA	Canadian Longitudinal Study on Aging
442	SARS-CoV-2	Severe acute respiratory syndrome coronavirus-2

443

444 **DECLARATIONS**

445 **Ethics approval and consent to participate**

446 All studies analyzed were approved by a Research Ethics Board or Institutional Review Board of
447 a Canadian institution as reported previously. This secondary analysis of six studies was
448 approved by the McGill University Faculty of Medicine and Health Sciences Research Ethics
449 Board (study number 22-03-077).

450 **Consent for participation**

451 Not applicable.

452 **Availability of data and materials**

453 The authors are not authorized to share individual-level data from any study. Processes are
454 available for researchers to request access to datasets for studies that have undergone
455 institutional ethical approval. Data from Canadian Blood Services and Alberta Precision

456 Laboratories may be made available upon request, subject to internal review, privacy legislation,
457 data sharing agreements, and research ethics approval. The CCAHS-1 study by Statistics Canada
458 can be analyzed for approved projects at Research Data Centres located across Canada
459 (<https://www.statcan.gc.ca/en/microdata/data-centres/access>). Data are available from the
460 Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria
461 for access to de-identified CLSA data. Access to the Ab-C study data can be requested through
462 the COVID-19 Immunity Task Force Databank (<https://portal.citf.mcgill.ca/>). Access to the
463 CanPath data can be requested through the CanPath data portal (<https://portal.canpath.ca/>).
464 Analytical code will be available in a public repository upon publication.

465 **Competing interests**

466 The authors declare that they have no competing interests.

467 **Funding**

468 WAR was supported by funding from Canadian Blood Services and the COVID-19 Immunity
469 Task Force.

470 **Authors' contributions**

471 MJK and WAR designed the study with input from DLB, SFO, and CC. MJK, YY, and JC
472 contributed to data analysis. MJK and WAR drafted the initial manuscript. All
473 authors revised the manuscript and approved the final version.

474 **Acknowledgements**

475 This research was made possible using data collected by Canadian Blood Services' SARS-CoV-
476 2 Seroprevalence Study; the Canadian Partnership for Tomorrow's Health (CanPath – formerly
477 CPTP) COVID-19 Antibody study and its regional cohorts the BC Generations Project, Alberta's
478 Tomorrow Project, the Ontario Health Study, CARTaGENE, Manitoba Tomorrow Project and

479 the Atlantic Partnership for Tomorrow’s Health; the Action to Beat Coronavirus in Canada (Ab-
480 C) study; the Alberta Precision Laboratories study; the Canadian COVID-19 Antibody and
481 Health Survey (CCAHS) conducted by Statistics Canada, and the Canadian Longitudinal Study
482 on Aging (CLSA). We thank the participants, staff, and researchers of all six studies. We also
483 thank Scott McLeish for the insightful discussions which greatly improved the quality of the
484 manuscript. Funding for the CLSA is provided by the Government of Canada through the
485 Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the
486 Canada Foundation for Innovation, as well as the provinces, Newfoundland, Nova Scotia,
487 Quebec, Ontario, Manitoba, Alberta, and British Columbia. Funding for support of the CLSA
488 COVID-19 questionnaire-based study is provided by the Juravinski Research Institute, Faculty of
489 Health Sciences, McMaster University, the Provost Fund from McMaster University, the
490 McMaster Institute for Research on Aging, the Public Health Agency of Canada/CIHR grant
491 reference CMO 174125 and the government of Nova Scotia. This research has been conducted
492 using the CLSA Baseline Comprehensive Dataset v7.0, Baseline Tracking Dataset v4.0, Follow-
493 up 1 Comprehensive Dataset v4.0, Follow-up 1 Tracking Dataset v3.0, Follow-up 2
494 Comprehensive Dataset v1.0, Follow-up 2 Tracking Dataset v1.0, COVID-19 Questionnaire
495 Study Dataset v1.1, and COVID-19 Seroprevalence Study Dataset v1.0 under Application
496 Number 2209005. The CLSA is led by Drs. Parminder Raina, Christina Wolfson, and Susan
497 Kirkland. We appreciate the funding that made each study possible, including the support each
498 study received from the Government of Canada through the COVID-19 Immunity Task Force.
499 The opinions expressed in this manuscript are the author’s own and do not reflect the views of
500 the data providers and/or their institutions.

501

502 REFERENCES

- 503 1. O'Brien SF, Caffrey N, Yi QL, et al. Cross-Canada Variability in Blood Donor SARS-
504 CoV-2 Seroprevalence by Social Determinants of Health. *Microbiology Spectrum*.
505 2023;11(1):e03356-22. [10.1128/spectrum.03356-22](https://doi.org/10.1128/spectrum.03356-22)
- 506 2. Charlton CL, Nguyen LT, Bailey A, et al. Pre-Vaccine Positivity of SARS-CoV-2
507 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
508 *Microbiology Spectrum*. 2021;9(1):e00291-21. [10.1128/Spectrum.00291-21](https://doi.org/10.1128/Spectrum.00291-21)
- 509 3. Jha, Prabhat. Action to beat Coronavirus study: Dataset contributed to the CITF
510 Databank. Version DRAFT. Borealis. <https://doi.org/doi:10.5683/SP3/LA2IKO>
- 511 4. Canadian Longitudinal Study on Aging. Data Support Document SARS-CoV-2
512 Antibodies. 2024.
- 513 5. Canadian Partnership for Tomorrow's Health. COVID-19 initiatives. CanPath - Canadian
514 Partnership for Tomorrow's Health. Available from: <https://canpath.ca/covid-19-initiatives/>.
- 515 6. Statistics Canada. Canadian COVID-19 Antibody and Health Survey (CCAHS). 2020.
516 Available from:
517 <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1287991>
- 518 7. Cornesse C, Bosnjak M. Is there an association between survey characteristics and
519 representativeness? A meta-analysis. *Survey Research Methods*. 2018;12(1):1-13.
520 [10.18148/srm/2018.v12i1.7205](https://doi.org/10.18148/srm/2018.v12i1.7205)
- 521 8. Offergeld R, Preußel K, Zeiler T, et al. Monitoring the SARS-CoV-2 Pandemic:
522 Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in

- 523 Germany—Results from the SeBluCo Study 2020–2022. *Pathogens*. 2023;12(4):551.
524 [10.3390/pathogens12040551](https://doi.org/10.3390/pathogens12040551)
- 525 9. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-
526 CoV-2 IgG antibodies, Greece, March and April 2020. *Eurosurveillance*.
527 2020;25(31):2001369. [10.2807/1560-7917.ES.2020.25.31.2001369](https://doi.org/10.2807/1560-7917.ES.2020.25.31.2001369)
- 528 10. Pérez-Gómez B, Pastor-Barriuso R, Fernández-de-Larrea N, et al. SARS-CoV-2
529 Infection During the First and Second Pandemic Waves in Spain: The ENE–COVID Study.
530 *Am J Public Health*. 2023;113(5):533-544. [10.2105/AJPH.2023.307233](https://doi.org/10.2105/AJPH.2023.307233)
- 531 11. Ward H, Atchison C, Whitaker M, et al. Design and Implementation of a National
532 Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-
533 Testing: The REACT-2 Study. *Am J Public Health*. 2023;113(11):1201-1209.
534 [10.2105/AJPH.2023.307381](https://doi.org/10.2105/AJPH.2023.307381)
- 535 12. Tang X, Sharma A, Pasic M, et al. Assessment of SARS-CoV-2 Seropositivity During
536 the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. *JAMA*
537 *Network Open*. 2022;5(2):e2146798. [10.1001/jamanetworkopen.2021.46798](https://doi.org/10.1001/jamanetworkopen.2021.46798)
- 538 13. Patel EU, Bloch EM, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2
539 Serosurveillance in Blood Donor Populations. *The Journal of Infectious Diseases*.
540 2022;225(1):1-4. [10.1093/infdis/jiab517](https://doi.org/10.1093/infdis/jiab517)
- 541 14. Rudolph JE, Zhong Y, Duggal P, et al. Defining representativeness of study samples in
542 medical and population health research. *BMJ Med*. 2023;2(1):e000399. [10.1136/bmjmed-](https://doi.org/10.1136/bmjmed-2022-000399)
543 [2022-000399](https://doi.org/10.1136/bmjmed-2022-000399)

- 544 15. Raina P, Wolfson C, Kirkland S, et al. Cohort Profile: The Canadian Longitudinal Study
545 on Aging (CLSA). *International Journal of Epidemiology*. 2019;48(6):1752-1753j.
546 [10.1093/ije/dyz173](https://doi.org/10.1093/ije/dyz173)
- 547 16. Dummer TJB, Awadalla P, Boileau C, et al. The Canadian Partnership for Tomorrow
548 Project: A pan-Canadian platform for research on chronic disease prevention. *CMAJ*.
549 2018;190(23):E710-E717. [10.1503/cmaj.170292](https://doi.org/10.1503/cmaj.170292)
- 550 17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
551 Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting
552 observational studies. *Epidemiology*. 2007;18(6):800-804.
- 553 18. Pampalon R, Hamel D, Gamache P, et al. An area-based material and social deprivation
554 index for public health in Québec and Canada. *Can J Public Health*. 2012;103(8 Suppl
555 2):S17-22. [10.1007/BF03403824](https://doi.org/10.1007/BF03403824)
- 556 19. Statistics Canada. Census Profile, 2016 Census. 2017. Available from:
557 <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E>
- 558 20. Downes M, Carlin JB. Multilevel regression and poststratification as a modeling
559 approach for estimating population quantities in large population health studies: A simulation
560 study. *Biometrical Journal*. 2020;62(2):479-491. [10.1002/bimj.201900023](https://doi.org/10.1002/bimj.201900023)
- 561 21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
562 Austria: R Foundation for Statistical Computing; 2023. <https://www.R-project.org/>.
- 563 22. Lindan CP, Desai M, Boothroyd D, et al. Design of a population-based longitudinal
564 cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco
565 Bay Area. *Annals of Epidemiology*. 2022;67:81-100. [10.1016/j.annepidem.2021.11.001](https://doi.org/10.1016/j.annepidem.2021.11.001)

- 566 23. Yu Y, Knight MJ, Gibson D, et al. Temporal trends in disparities in COVID-19
567 seropositivity among Canadian blood donors. *International Journal of Epidemiology*.
568 2024;53(3):dyae078. [10.1093/ije/dyae078](https://doi.org/10.1093/ije/dyae078)
- 569 24. Froom P, Melamed S, Kristal-Boneh E, et al. Healthy Volunteer Effect in Industrial
570 Workers. *Journal of Clinical Epidemiology*. 1999;52(8):731-735. [10.1016/S0895-
571 4356\(99\)00070-0](https://doi.org/10.1016/S0895-4356(99)00070-0)
- 572 25. Atsma F, Veldhuizen I, Verbeek A, et al. Healthy donor effect: Its magnitude in health
573 research among blood donors. *Transfusion*. 2011;51(8):1820-1828. doi:[10.1111/j.1537-
574 2995.2010.03055.x](https://doi.org/10.1111/j.1537-2995.2010.03055.x)
- 575 26. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
576 nationwide sample of patients on dialysis in the USA: A cross-sectional study. *The Lancet*.
577 2020;396(10259):1335-1344. doi:[10.1016/S0140-6736\(20\)32009-2](https://doi.org/10.1016/S0140-6736(20)32009-2)
- 578 27. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-
579 CoV-2 antibody detection using the Roche Elecsys® high throughput immunoassay. *Journal*
580 *of Clinical Virology*. 2021;136:104739. [10.1016/j.jcv.2021.104739](https://doi.org/10.1016/j.jcv.2021.104739)
- 581 28. Patel EU, Bloch EM, Clarke W, et al. Comparative Performance of Five Commercially
582 Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals
583 with High Neutralizing Titers. *Journal of Clinical Microbiology*.
584 2021;59(2):10.1128/jcm.02257-20. [10.1128/jcm.02257-20](https://doi.org/10.1128/jcm.02257-20)
- 585 29. Etti M, Fofie H, Razai M, et al. Ethnic minority and migrant underrepresentation in
586 Covid-19 research: Causes and solutions. *eClinicalMedicine*. 2021;36.
587 [10.1016/j.eclinm.2021.100903](https://doi.org/10.1016/j.eclinm.2021.100903)

- 588 30. Bonevski B, Randell M, Paul C, et al. Reaching the hard-to-reach: A systematic review of
589 strategies for improving health and medical research with socially disadvantaged groups.
590 BMC Medical Research Methodology. 2014;14(1):42. [10.1186/1471-2288-14-42](https://doi.org/10.1186/1471-2288-14-42)
- 591 31. Ekezie W, Czyznikowska BM, Rohit S, et al. The views of ethnic minority and
592 vulnerable communities towards participation in COVID-19 vaccine trials. Journal of Public
593 Health. 2021;43(2):e258-e260. [10.1093/pubmed/fdaa196](https://doi.org/10.1093/pubmed/fdaa196)
- 594 32. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
595 nationwide sample of patients on dialysis in the USA: A cross-sectional study. The Lancet.
596 2020;396(10259):1335-1344. [10.1016/S0140-6736\(20\)32009-2](https://doi.org/10.1016/S0140-6736(20)32009-2)
- 597 33. Khan MM, Kobayashi K, Vang ZM, et al. Are visible minorities “invisible” in Canadian
598 health data and research? A scoping review. International Journal of Migration, Health and
599 Social Care. 2017;13(1):126-143. [10.1108/IJMHSC-10-2015-0036](https://doi.org/10.1108/IJMHSC-10-2015-0036)
- 600 34. Patel EU, Bloch EM, Grabowski MK, et al. Sociodemographic and behavioral
601 characteristics associated with blood donation in the United States: A population-based
602 study. Transfusion. 2019;59(9):2899-2907. [10.1111/trf.15415](https://doi.org/10.1111/trf.15415)
- 603 35. Atkinson A, Albert A, McClymont E, et al. Canadian SARS-CoV-2 serological survey
604 using antenatal serum samples: A retrospective seroprevalence study. Canadian Medical
605 Association Open Access Journal. 2023;11(2):E305-E313. [10.9778/cmajo.20220045](https://doi.org/10.9778/cmajo.20220045)